Drug Profile


Alternative Names: TXA 127

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tarix Orphan; Tarix Pharmaceuticals
  • Developer Tarix Orphan; Tarix Pharmaceuticals; Unigene Laboratories; US Biotest Inc
  • Class Antihypertensives; Heart failure therapies; Peptide hormones
  • Mechanism of Action Haematopoietic cell growth factor stimulants; Proto-oncogene protein c-mas-1 agonists; Transforming growth factor beta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Pulmonary arterial hypertension; Limb girdle muscular dystrophies; Muscular dystrophies; Duchenne muscular dystrophy; Stem cell engraftment; Myelodysplastic syndromes
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Connective tissue disorders; Duchenne muscular dystrophy; Epidermolysis bullosa; Limb girdle muscular dystrophies; Muscular dystrophies
  • Discontinued Adult respiratory distress syndrome; HIV infections; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Stroke; Thrombocytopenia

Most Recent Events

  • 12 Jun 2017 Angiotensin-1-7 receives Orphan Drug status for Epidermolysis bullosa in European Union
  • 18 Jan 2017 Angiotensin-1-7 receives rare paediatric disease designation status for Epidermolysis bullosa in USA
  • 07 Sep 2016 Angiotensin-1-7 receives Orphan Drug status for Epidermolysis bullosa in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top